Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Berkshire Hathaway Inc Class B (BRK.B) vs ResMed Inc. (RMD) Price & Performance

Berkshire Hathaway Inc Class BTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Berkshire Hathaway Inc Class B vs ResMed Inc. — how do they compare? Berkshire Hathaway Inc Class B trades at $509.73, while ResMed Inc. trades at $225.93 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while Berkshire Hathaway Inc Class B pays none, and Berkshire Hathaway Inc Class B is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.

BRK.BRMD
Sector
FinancialsHealth
52-Week High
$529.65$293.73
52-Week Low
$465.39$182.82
Market Cap
$32.61B
Enterprise Value
$31.97B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Berkshire Hathaway Inc Class B

BRK.B trades at $509.58, down 3.79% on the day, with technical indicators showing a bullish trend from moving averages and strong directional momentum (ADX). Analyst consensus is positive with 57% buy ratings and no sell recommendations. The stock is near key support at $510 and resistance at $522, indicating a critical price zone.

The outlook remains favorable given strong institutional support and bullish technicals, but risks include market volatility and Berkshire Hathaway's exposure to economic cycles. Upside potential hinges on execution across its diversified holdings, while any broad market downturn could pressure the stock.

ResMed Inc.

ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.

The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Berkshire Hathaway Inc Class B

Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.

Read more on BRK.B

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD